Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections.
Int J Antimicrob Agents. 2016 Jun 8;
Authors: Lee N, Chan PK, Tam WW, Chan MC, Lui GC, Kwok AK, Ko FW, Ng SS, Yung IM, Wong RY, Hui DS
Abstract
An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log10 copies/mL [βinteraction -0.071, standard error (SE) 0.121, 95% confidence interval (CI) -0.309 to 0.167]; culture-negative, 94% (vs. 95%); and RNA-negative, 44% (vs. 36%). Extended treatment of >5 days was required in 69% of cases because of slow clinical resolution and viral clearance in LRTCs. Peramivir was well tolerated. These data are useful for future trial design in this unique population.
PMID: 27319273 [PubMed - as supplied by publisher]